Andremont 1981.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 48 adults (macrolide n = 24, placebo n = 24) Age in years: N/A Setting: healthy US residents travelling to Mexico to attend a professional meeting
Interventions	Indication: prevention of traveller's diarrhoea Type of macrolide: erythromycin base Route: per oral Dose per day: 1000 mg Duration of treatment: mean days of treatment 6 (range 4 to 13 days) Total treatment dose: 6000 mg (mean)
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: no Adverse events ascertainment: unclear Adverse events: states that no adverse events were reported Antimicrobial resistance: not reported Death: not reported
Funding sources	Study supported by a "contrat de recherche clinique" from Institut Gustave Roussy and a grant from Roussel‐Uclaf Laboratories.
Notes	Concomitant medication: unclear Note: gastrointestinal symptoms were reported as the primary outcome in this study and not reported/regarded as an adverse event.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomisation
Allocation concealment (selection bias)	Unclear risk	Allocation not described.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical‐appearing placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding of participants and clinicians
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropout
Selective reporting (reporting bias)	Unclear risk	Adverse events not stated as an outcome and unclear ascertainment. However, states that no adverse events were reported.
Other bias	Low risk	None were identified.